在癌症中对KRAS途径的治疗向方面取得的最新进展
Nadia Hitchen1, Sarah Williams1, Jayesh Desai2
1Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Pharmacology & therapeutics
|May 30, 2025
概括
用新的抑制剂向基斯鼠肉瘤病毒 (KRAS) 突变显示出治疗肺癌和结直肠癌等癌症的前景. 需要进一步的研究来优化治疗方法,以获得更好的患者结果.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 针对性抑制大鼠肉瘤病毒 (RAS) 信号通路是癌症治疗的关键进展.
- 基斯大鼠肉瘤病毒 (KRAS) 突变在非小细胞肺癌 (NSCLC),结直肠癌 (CRC) 和胰腺管道腺癌 (PDAC) 中普遍存在.
- KRAS突变在历史上被认为是"不可抗药的",但现在被特定的抑制剂准.
研究的目的:
- 审查针对KRAS突变的近期治疗进展.
- 要突出KRAS特异性抑制剂的临床发展.
- 讨论未来克服耐药性和改善癌症控制的战略.
主要方法:
- 审查最近的科学文献和临床试验数据.
- 分析KRAS抑制剂如索托拉西布,阿达格拉西布和迪瓦拉西布的疗效.
- 探索组合策略和未来的治疗方法.
主要成果:
- 克拉斯抑制剂,特别是克拉斯12C和克拉斯12D突变,显示出有前途的临床结果.
- 索托拉西布和阿达格拉西布等药物对KRASG12C突变有效,特别是在NSCLC中.
- 组合疗法已经显示出改善的结果,特别是在CRC.
结论:
- 向KRAS是癌症治疗中快速扩大的领域,目前有50多种药物正在开发中.
- 挑战包括优化临床试验设计和整合剂量和时间表的药学动力学工具.
- 未来的策略包括结合突变特异和突变独立的方法来克服耐药性并提供更持久的癌症控制.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
7.9K
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Small GTPases - Ras and Rho
3.9K
Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
Three regulatory proteins control their activity:
3.9K
